The FDA has directed manufacturers of all drug products approved for the treatment of attention deficit hyperactivity disorder (ADHD) to develop Patient Medication Guides to alert patients of possible cardiovascular risks and risks of adverse psychiatric symptoms associated with the medicines, and to advise them of precautions that can be taken.

For more information visit www.fda.gov/cder/drug/infopage/ADHD/default.htm.